Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. (2nd January 2020)

• Record Type: Journal Article
• Authors: Rosenblatt, Robert; Lorentzi, Gabriella; Bahar, Maryam; Asad, Danna; Forsman, Ramona; Johansson, Markus; Shareef, Marwan; Alamdari, Farhood; Bergh, Anders; Winqvist, Ola; Sherif, Amir
• Is Part Of: Scandinavian journal of urology. Volume 54:Number 1(2020)
• Page Start: 46
• Page End: 51
• Publication Date: 2020-01-02
• Subjects: Urinary bladder cancer -- neoadjuvant therapies -- erythrocyte transfusions -- cystectomy -- survival analysis -- transfusion related immunomodulation; Urology -- Periodicals; 616.6
• DOI: 10.1080/21681805.2020.1716067
• Languages: English
• ISSNs: 2168-1805

Abstract

Abstract: Objective: To evaluate the extent and plausible effects of blood transfusions given during cisplatin-based neoadjuvant chemotherapy (NAC) on overall survival in patients with muscle-invasive urothelial bladder cancer (MIBC) undergoing NAC and radical cystectomy (RC). Background: Several studies have demonstrated a decreased survival for MIBC patients receiving allogenic peri- and postoperative blood transfusions in conjunction with RC. No studies have previously investigated the effects of blood transfusions during NAC. Materials and methods: 120 patients with MIBC (cT2-T4aN0M0) undergoing NAC and RC between 2008 and 2014 at four Swedish cystectomy centers were retrospectively evaluated. Clinicopathological data were obtained, including data of allogenic blood administration. Survival data was analyzed by Kaplan–Meier plotting and Cox regression. Results: One third of the cohort received blood transfusions during the period of NAC. In univariate analysis, blood transfusions during NAC, nodal stage and advanced tumor stage (pT >2) were negative prognostic factors for survival. In multivariate analysis, only pNx and pT >2 remained significant negative prognostic factors. In a subgroup analysis consisting of patients with localized tumors without dissemination ( n = 96), patients that received transfusions during NAC showed an 18.5% absolute risk increase of death at five years of observation, although without statistical significance ( p = .197). Conclusions: This is the first time that the extent and plausible effects of allogenic blood transfusions during NAC is examined in MIBC. Data suggest that there may be an association between blood transfusion and poor pathological and oncological outcome. Firm conclusions are difficult to draw due to few study participants and the retrospective nature of the study.